Friday, November 20, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 59

Medtronic's Hugo robot clears FDA for general surgery

Medtronic won FDA clearance to use its Hugo robotic-assisted surgery system in general surgery in the U.S., pushing it well past its old urology-only approval. That unlocks a pool of roughly 3.5 million abdominal procedures a year. Now the question is whether Hugo hits its 50,000-procedure target.

By the Paparazzi desk November 20, 2026 · 2:13 AM · finance.yahoo.com · 1 view
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 20, 2026 at 2:13 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The FDA has cleared Medtronic's Hugo robotic-assisted surgery system for general surgery procedures in the U.S. The authorization widens Hugo's approved use beyond urologic surgery into a broader set of abdominal and soft-tissue operations. General surgery accounts for about 3.5 million procedures a year in the U.S., which significantly expands the robot's potential caseload.

Medtronic comes to this with scale: the medical equipment group carries a market cap of roughly $123.3B and has spent more than 50 years selling open and laparoscopic tools into these same abdominal and soft-tissue procedures. That means Hugo drops into hospital relationships Medtronic already has. The company also points to the robot's modular design and its integration of LigaSure vessel sealing, which has been used in over 45 million procedures, as reasons hospitals that already buy its instruments would find Hugo flexible.

Sponsored

The adoption curve is the real story. Hugo procedures globally are running at more than two times the robotic surgery market and are expected to exceed 50,000 by the end of Medtronic's current fiscal year. Medtronic sits among the large device makers riding growth in surgical and AI-enabled infrastructure.

That 50,000 figure is the marker to watch. Hitting it — or missing it — will show how fast hospitals are actually moving general surgery cases onto Hugo, and how much of that 3.5-million-procedure pool is beginning to convert.

TopicsMedtronic · Hugo · FDA · LigaSure · NYSE:MDT

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 11:31 UTC · 1 hour ago · wired.com · 1 view
    El Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
  • Health & science 11:16 UTC · 2 hours ago · biobuzz.io · 1 view
    FDA approves AstraZeneca's once-weekly Klygefa for generalised myasthenia gravis
  • Health & science 11:16 UTC · 2 hours ago · theguardian.com · 1 view
    Pancreatic cancer pill erases tumours in 1 in 12 patients, trial finds
  • Health & science 05:44 UTC · 7 hours ago · pluang.com · 1 view
    Galleri wins FDA panel nod as GRAIL chases first multi-cancer screening approval
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.